» Articles » PMID: 34188042

Resolution of Tissue Signatures of Therapy Response in Patients with Recurrent GBM Treated with Neoadjuvant Anti-PD1

Overview
Journal Nat Commun
Specialty Biology
Date 2021 Jun 30
PMID 34188042
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

The response of patients with recurrent glioblastoma multiforme to neoadjuvant immune checkpoint blockade has been challenging to interpret due to the inter-patient and intra-tumor heterogeneity. We report on a comparative analysis of tumor tissues collected from patients with recurrent glioblastoma and high-risk melanoma, both treated with neoadjuvant checkpoint blockade. We develop a framework that uses multiplex spatial protein profiling, machine learning-based image analysis, and data-driven computational models to investigate the pathophysiological and molecular factors within the tumor microenvironment that influence treatment response. Using melanoma to guide the interpretation of glioblastoma analyses, we interrogate the protein expression in microscopic compartments of tumors, and determine the correlates of cytotoxic CD8+ T cells, tumor growth, treatment response, and immune cell-cell interaction. This work reveals similarities shared between glioblastoma and melanoma, immunosuppressive factors that are unique to the glioblastoma microenvironment, and potential co-targets for enhancing the efficacy of neoadjuvant immune checkpoint blockade.

Citing Articles

Anti-PD-1 and anti-PD-L1 antibodies for glioma.

de Melo S, Elias Nunes da Silva M, Torloni M, Riera R, De Cicco K, Latorraca C Cochrane Database Syst Rev. 2025; 1:CD012532.

PMID: 39777725 PMC: 11707826. DOI: 10.1002/14651858.CD012532.pub2.


The current landscape of spatial biomarkers for prediction of response to immune checkpoint inhibition.

Williams H, Frei A, Koessler T, Berger M, Dawson H, Michielin O NPJ Precis Oncol. 2024; 8(1):178.

PMID: 39138341 PMC: 11322473. DOI: 10.1038/s41698-024-00671-1.


Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways.

Skadborg S, Maarup S, Draghi A, Borch A, Hendriksen S, Mundt F Cancer Immunol Res. 2024; 12(9):1202-1220.

PMID: 38885356 PMC: 11369628. DOI: 10.1158/2326-6066.CIR-23-0959.


Biomaterial-based 3D modeling of glioblastoma multiforme.

Ahmed T Cancer Pathog Ther. 2024; 1(3):177-194.

PMID: 38327839 PMC: 10846340. DOI: 10.1016/j.cpt.2023.01.002.


WNT/β-catenin regulatory roles on PD-(L)1 and immunotherapy responses.

Mortezaee K Clin Exp Med. 2024; 24(1):15.

PMID: 38280119 PMC: 10822012. DOI: 10.1007/s10238-023-01274-z.


References
1.
Ostrom Q, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y . CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol. 2013; 15 Suppl 2:ii1-56. PMC: 3798196. DOI: 10.1093/neuonc/not151. View

2.
Quail D, Joyce J . The Microenvironmental Landscape of Brain Tumors. Cancer Cell. 2017; 31(3):326-341. PMC: 5424263. DOI: 10.1016/j.ccell.2017.02.009. View

3.
Reardon D, Brandes A, Omuro A, Mulholland P, Lim M, Wick A . Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020; 6(7):1003-1010. PMC: 7243167. DOI: 10.1001/jamaoncol.2020.1024. View

4.
Gershenwald J, Scolyer R, Hess K, Sondak V, Long G, Ross M . Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017; 67(6):472-492. PMC: 5978683. DOI: 10.3322/caac.21409. View

5.
Weber J, Mandala M, Del Vecchio M, Gogas H, Arance A, Cowey C . Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med. 2017; 377(19):1824-1835. DOI: 10.1056/NEJMoa1709030. View